top of page
Selected Publications
PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer
Chauhan SS, Casillas AL, Vizzerra AD, Liou H, Clements AN, Flores CE, Prevost CT, Kashatus DF, Snider AJ, Snider JM, Warfel NA. Oncogene. 2023 PubMed PMID: 38097734.
​

PIM1 targeted degradation prevents the emergence of chemoresistance in prostate cancer.
Torres-Ayuso P, Katerji M, Mehlich D, Lookingbill SA, Sabbasani VR, Liou H, Casillas AL, Chauhan SS, Serwa R, Rubin MR, Marusiak AA, Swenson RE, Warfel NA, Brognard J. Cell Chem Biol. 2023. PMID: 38016478.

PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion.
Jensen CC, Clements AN, Liou H, Ball LE, Bethard JR, Langlais PR, Toth RK, Chauhan SS, Casillas AL, Daulat SR, Kraft AS, Cress AE, Miranti CK, Mouneimne G, Rogers GC, Warfel NA. J Cell Biol. 2023 PubMed Central PMCID: PMC10103708.
Direct phosphorylation and stabilization of HIF-1α by PIM1 kinase drives angiogenesis in solid tumors. Casillas AL, Chauhan SS, Toth RK, Sainz AG, Clements AN, Jensen CC, Langlais PR, Miranti CK, Cress AE, Warfel NA. Oncogene. 2021
Hypoxia-inducible PIM kinase expression promotes resistance to antiangiogenic agents. A.L. Casillas, R.K. Toth, N. Singh, A.A. Desai, A.S. Kraft, and N.A. Warfel. Clinical Cancer Research 2018.
bottom of page